Compare LMND & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LMND | IMVT |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 5.3B |
| IPO Year | 2020 | N/A |
| Metric | LMND | IMVT |
|---|---|---|
| Price | $80.74 | $26.38 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 9 |
| Target Price | ★ $56.25 | $28.38 |
| AVG Volume (30 Days) | ★ 2.3M | 2.1M |
| Earning Date | 02-24-2026 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $658,300,000.00 | N/A |
| Revenue This Year | $40.13 | N/A |
| Revenue Next Year | $59.80 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 33.66 | N/A |
| 52 Week Low | $24.31 | $12.72 |
| 52 Week High | $85.20 | $27.69 |
| Indicator | LMND | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 57.48 | 56.91 |
| Support Level | $69.69 | $24.70 |
| Resistance Level | $84.84 | $27.38 |
| Average True Range (ATR) | 3.96 | 1.04 |
| MACD | -0.02 | -0.13 |
| Stochastic Oscillator | 72.57 | 54.76 |
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes. The company is using technology, data, artificial intelligence, contemporary design, and social impact to deliver delightful and affordable insurances. Geographically, it operates in California, Texas, New York, New Jersey, Illinois, Georgia, Washington, Colorado, Pennsylvania, Oregon and others.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.